FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058771876> ?p ?o ?g. }

• W2058771876 endingPage "132" @default.
• W2058771876 startingPage "130" @default.
• W2058771876 abstract "Acute myeloid leukaemia (AML) varies greatly in response to therapy. Although cytogenetics is the most important predictor of response, it is least informative in the 40–50% of adults with normal cytogenetics (Grimwade et al, 1998). However, an increasing number of molecular markers with prognostic significance, particularly in cytogenetically normal AML (CN-AML), have been identified. The two most common are internal tandem duplications (ITD) in the FLT3 gene (FLT3-ITD) and mutations in the nucleophosmin gene (NPM1) with frequencies of approximately 50% and 30%, respectively, in CN-AML. While FLT3-ITD is associated with short relapse-free and overall survival, the prognosis of CN-AML with NPM1 mutations without FLT3-ITD (NPM+/FLT3-ITD-) is similar to that of “favourable” cytogenetics AML (Kottaridis et al, 2001; Thiede et al, 2002; Schnittger et al, 2005). NPM1 and FLT3-ITD are often used to guide decisions about therapy in first complete remission (CR). In particular, the high relapse rate of FLT3-ITD+ AML leads to use of allogeneic haematopoietic cell transplant (HCT) while the lower relapse rate of NPM+/FLT3-ITD- leads to administration of repetitive cycles of high dose cytarabine (Döhner et al, 2010; Brunet et al, 2012). Despite their prognostic relevance, FLT3-ITD and NPM1 status at diagnosis is often unknown when patients are referred in first CR to tertiary centres. Here we report efforts to develop a multivariate model based on other clinical and laboratory data to predict probability of a patient being FLT3-ITD+ or NPM1+/FLT3-ITD-. Our hypothesis was that examining covariates in combination would add to predictive ability in contrast to examining them singly. Our analysis included 434 adults with newly diagnosed AML (excluding acute promyelocytic leukaemia) treated on four Southwest Oncology Group (SWOG) trials (S9031, S9333, S9500, and S0106). Details of the treatment protocols have been previously reported (Godwin et al, 1998; Anderson et al, 2002; Petersdorf et al, 2007, 2013). Two independent validation cohorts were 1401 patients treated on various protocols at the MD Anderson Cancer Center (MDA) and 210 patients treated on various protocols at Fred Hutchinson Cancer Research Center (FHCRC). Institutional review boards of participating institutions approved all protocols, and patients were treated according to the Declaration of Helsinki. FLT3-ITD and NPM1 status (positive/negative) was established at diagnosis in all patients included in this study. Univariate and multivariate logistic regression models were used to identify covariates associated with being (1) FLT3-ITD+ and (2) NPM1+/FLT3-ITD- at diagnosis. Covariates examined were age, sex, performance status (PS), white blood cell count (WBC), platelet count, bone marrow blast percentage, secondary AML, and cytogenetic risk (using SWOG criteria). The relative ability of covariates to predict outcomes was quantified using the area under the receiver operator characteristic curve (AUC); an AUC of 1·0 denotes perfect prediction, whereas an AUC of 0·5 is analogous to a coin flip. The scoring systems were tested in the two independent populations (MDA and FHCRC). Characteristics of the 428 patients treated on SWOG trials are summarized in Table 1. FLT3-ITD was present in 23·6% (101 out of 428). WBC>20 × 109/l and normal cytogenetics had the largest AUCs for predicting FLT3-ITD positivity: 0·65 and 0·69, respectively (Table 1). A multivariate model indicated that WBC >20 × 109/l (odds ratio 3·4 vs. WBC <20 × 109/l, P < 0·001), SWOG favourable cytogenetics (odds ratio 0·06 vs. normal cytogenetics, P < 0·001) and SWOG unfavourable cytogenetics, (odds ratios 0·23 vs. normal cytogenetics, P < 0·001) were independently associated with being FLT3-ITD+ at diagnosis. The AUC of a model combining these features was 0·79 and contrasted with 0·65 and 0·69, respectively, when only WBC or cytogenetics were considered. We then tested the multivariate model's performance in the MDA and FHCRC populations that had not contributed to the system's development and in whom FLT3-ITD status at diagnosis was known. In the FHCRC population (16% FLT3-ITD positive) its AUC was only 0·58, not better than when each covariate was examined separately (AUC 0·54 and 0·6 for WBC and cytogenetics, respectively). Similarly, at MDA (17% FLT3-ITD positive), the system's AUC was 0·68 versus AUC of 0·59 and 0·68 for WBC and cytogenetics, respectively. A similar approach was used to identify covariates associated with being NPM1+/FLT3-ITD-. Characteristics of SWOG patients with NPM1+/FLT3-ITD- and FLT3-ITD+ (with or without NPM1) or FLT3-ITD-/NPM1- treated on SWOG trials are summarized in Table 2. NPM1+/FLT3-ITD- was present in 16% (63 of the 401). Cytogenetics was associated with NPM1+/FLT3-ITD- with AUC of 0·73 and multivariate analysis indicated that the only covariate independently associated with NPM1+/FLT3-ITD- was cytogenetics. As the AUC of the multivariate model (0·79) was only slightly better than what had been observed with cytogenetics alone, we did not attempt to verify the model in the MDA and FHCRC populations. FLT3-ITD and NPM1 are used to assign patients to HCT (FLT3-ITD+) or repetitive cycles of chemotherapy (NPM1+/FLT3-ITD-). However FLT3-ITD+ and NPM1+ status at diagnosis is often unknown when patients are referred to tertiary centres after reaching CR. This prompted an attempt to develop multitvariate models to predict the probability of a patient being (a) FLT3-ITD+ or (b) NPM1+/FLT3-ITD- based on readily available covariates. Our hypothesis was that a combination of covariates would add to the ability to predict (a) or (b) beyond what could be predicted knowing single covariates, e.g. higher WBC or normal cytogenetics, known to be associated with NPM1 + and FLT3-ITD status. Using AUC to quantify predictive ability, we found that a combination of WBC >20 × 109/l and normal cytogenetics was more effective in predicting FLT3-ITD+ in SWOG patients than either WBC or cytogenetics. However this is not true when the model was applied to MDA or FHCRC patients. One possible explanation is that the proportion of FLT3-ITD patients was less at FHCRC (P = 0·04) or at MDA (P = 0·002) than in SWOG. We were not successful in bettering the predictive ability of cytogenetics for NPM1+/FLT3-ITD-. Hence our hypothesis was not supported, suggesting that there is no obvious substitute for actual data on FLT3-ITD and NPM1. This research was supported by the National Cancer Institute T32 CA09515 (to F.O). EE and FO designed the research study; FO, MO and EE analysed the data; RS collected the data; HK, FR, PH, SF, PB, JC, JP, SP, JG, CW, SP, AL, RW, DS, FA contributed patients to the studies; MO, EE and FO interpreted data; FO and EE wrote the manuscript; SM, FA, RW and DS revised it critically. All authors approved the submitted and final version. The authors declare no competing financial interests." @default.
• W2058771876 created "2016-06-24" @default.
• W2058771876 creator A5000750846 @default.
• W2058771876 creator A5002286772 @default.
• W2058771876 creator A5015140142 @default.
• W2058771876 creator A5026347795 @default.
• W2058771876 creator A5028772063 @default.
• W2058771876 creator A5030500582 @default.
• W2058771876 creator A5040412322 @default.
• W2058771876 creator A5041323189 @default.
• W2058771876 creator A5044399026 @default.
• W2058771876 creator A5049490094 @default.
• W2058771876 creator A5051018931 @default.
• W2058771876 creator A5054425800 @default.
• W2058771876 creator A5056405520 @default.
• W2058771876 creator A5057920623 @default.
• W2058771876 creator A5058845981 @default.
• W2058771876 creator A5061732223 @default.
• W2058771876 creator A5065716888 @default.
• W2058771876 creator A5075191087 @default.
• W2058771876 creator A5083798364 @default.
• W2058771876 creator A5090435894 @default.
• W2058771876 date "2013-07-06" @default.
• W2058771876 modified "2023-10-16" @default.
• W2058771876 title "A model for prediction of<i>FLT3</i>-ITD and<i>NPM1</i>(without<i>FLT3</i>-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia" @default.
• W2058771876 cites W1534965621 @default.
• W2058771876 cites W1995547716 @default.
• W2058771876 cites W2025338891 @default.
• W2058771876 cites W2068311105 @default.
• W2058771876 cites W2116858301 @default.
• W2058771876 cites W2124013844 @default.
• W2058771876 cites W2129615499 @default.
• W2058771876 cites W2132912591 @default.
• W2058771876 cites W2137691760 @default.
• W2058771876 cites W27031567 @default.
• W2058771876 doi "https://doi.org/10.1111/bjh.12450" @default.
• W2058771876 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4128010" @default.
• W2058771876 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23829510" @default.
• W2058771876 hasPublicationYear "2013" @default.
• W2058771876 type Work @default.
• W2058771876 sameAs 2058771876 @default.
• W2058771876 citedByCount "1" @default.
• W2058771876 countsByYear W20587718762023 @default.
• W2058771876 crossrefType "journal-article" @default.
• W2058771876 hasAuthorship W2058771876A5000750846 @default.
• W2058771876 hasAuthorship W2058771876A5002286772 @default.
• W2058771876 hasAuthorship W2058771876A5015140142 @default.
• W2058771876 hasAuthorship W2058771876A5026347795 @default.
• W2058771876 hasAuthorship W2058771876A5028772063 @default.
• W2058771876 hasAuthorship W2058771876A5030500582 @default.
• W2058771876 hasAuthorship W2058771876A5040412322 @default.
• W2058771876 hasAuthorship W2058771876A5041323189 @default.
• W2058771876 hasAuthorship W2058771876A5044399026 @default.
• W2058771876 hasAuthorship W2058771876A5049490094 @default.
• W2058771876 hasAuthorship W2058771876A5051018931 @default.
• W2058771876 hasAuthorship W2058771876A5054425800 @default.
• W2058771876 hasAuthorship W2058771876A5056405520 @default.
• W2058771876 hasAuthorship W2058771876A5057920623 @default.
• W2058771876 hasAuthorship W2058771876A5058845981 @default.
• W2058771876 hasAuthorship W2058771876A5061732223 @default.
• W2058771876 hasAuthorship W2058771876A5065716888 @default.
• W2058771876 hasAuthorship W2058771876A5075191087 @default.
• W2058771876 hasAuthorship W2058771876A5083798364 @default.
• W2058771876 hasAuthorship W2058771876A5090435894 @default.
• W2058771876 hasBestOaLocation W20587718761 @default.
• W2058771876 hasConcept C104317684 @default.
• W2058771876 hasConcept C126322002 @default.
• W2058771876 hasConcept C143998085 @default.
• W2058771876 hasConcept C2483381 @default.
• W2058771876 hasConcept C2779282312 @default.
• W2058771876 hasConcept C2993296363 @default.
• W2058771876 hasConcept C30481170 @default.
• W2058771876 hasConcept C53226629 @default.
• W2058771876 hasConcept C55493867 @default.
• W2058771876 hasConcept C71924100 @default.
• W2058771876 hasConcept C86803240 @default.
• W2058771876 hasConceptScore W2058771876C104317684 @default.
• W2058771876 hasConceptScore W2058771876C126322002 @default.
• W2058771876 hasConceptScore W2058771876C143998085 @default.
• W2058771876 hasConceptScore W2058771876C2483381 @default.
• W2058771876 hasConceptScore W2058771876C2779282312 @default.
• W2058771876 hasConceptScore W2058771876C2993296363 @default.
• W2058771876 hasConceptScore W2058771876C30481170 @default.
• W2058771876 hasConceptScore W2058771876C53226629 @default.
• W2058771876 hasConceptScore W2058771876C55493867 @default.
• W2058771876 hasConceptScore W2058771876C71924100 @default.
• W2058771876 hasConceptScore W2058771876C86803240 @default.
• W2058771876 hasIssue "1" @default.
• W2058771876 hasLocation W20587718761 @default.
• W2058771876 hasLocation W20587718762 @default.
• W2058771876 hasLocation W20587718763 @default.
• W2058771876 hasLocation W20587718764 @default.
• W2058771876 hasOpenAccess W2058771876 @default.
• W2058771876 hasPrimaryLocation W20587718761 @default.
• W2058771876 hasRelatedWork W2016218033 @default.
• W2058771876 hasRelatedWork W2046185566 @default.
• W2058771876 hasRelatedWork W2049644758 @default.
• W2058771876 hasRelatedWork W2055765936 @default.

• next